NCT02923128View on ClinicalTrials.gov

Whether Dexmedetomidine Can Improve the Prognosis of Elderly Patients With Postoperative Cognitive Dysfunction

PHASE4CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

October 31, 2020

Study Completion Date

October 31, 2020

Conditions
Postoperative Cognitive DysfunctionPostoperative Delirium
Interventions
DRUG

Dexmedetomidine

Dexmedetomidine 3 ug/kg is diluted to 150ml with 0.9% saline,continuous micro-pump infusion for 72 hours with 2ml/h speed.

DRUG

Sufentanyl

Sufentanyl 3 ug/kg is diluted to 150ml with 0.9% saline,continuous micro-pump infusion for 72 hours with 2ml/h speed.

DRUG

Saline

Saline is used to dilute other drugs

Trial Locations (1)

310022

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors
lead

Zhejiang Cancer Hospital

OTHER

NCT02923128 - Whether Dexmedetomidine Can Improve the Prognosis of Elderly Patients With Postoperative Cognitive Dysfunction | Biotech Hunter | Biotech Hunter